DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00241423

CompletedPhase 2

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione

Lead sponsor

AstraZeneca

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

2

Recruiting sites

—

Enrollment

30

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 25-50•HbA1c 7-10%

Primary endpoint

•Time-averaged serum glucose during a 24-hour period

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00241423
Org study IDH8O-US-GWAW

Timeline

Milestones

Study first posted2005-10-19estimated
Last update posted2015-02-23estimated
Study start2005-10 (month precision)
Primary completion2007-06actual (month precision)
Study completion2007-06actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Subject has an HbA1c between 7.0% and 10.0%, inclusive.
•Subject has a body mass index (BMI) >25 kg/m^2 and <50 kg/m^2.
•Subject is on a stable dose of metformin or metformin plus a thiazolidinedione.

Exclusion criteria

•Subject has been treated with any of the following medications: *exogenous insulin for more than 1 week within 3 months of screening, *sulfonylureas or meglitinides within 2 months of screening, *alpha-glucosidase inhibitors within 2 months of screening, *pramlintide acetate injection within 2 months of screening.
•Subject has received exenatide, GLP-1 analogs, DPP-IV inhibitors, or has participated in this study previously.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Time-averaged serum glucose during a 24-hour period

Time frame:Every half-hour to hour for 24 hours

descriptive, improvement

Secondary/protocol endpoint

To compare the effects of exenatide and placebo on serum glucose

Time frame:Each half-hour to 2 hours for 24 hours

Postprandial glucose

descriptive, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.